Current trends in molecular diagnostics of chronic myeloid leukemia

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012;87:1037–1045.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47:302–311.
   PubMed Web of Science ®Google Scholar
• Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1983;243:290–293.
   Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619–1630.
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441–453.
   PubMed Web of Science ®Google Scholar
• Chen YY, Peng C, Li DG, et al. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell. 2010;1:124–132.
   PubMed Web of Science ®Google Scholar
• Chen M, Gallipoli P, DeGeer D, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst. 2013;105:405–423.
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Groffen J. Philadelphia-positive leukemia: a personal perspective. Oncogene. 2002;21:8536–8540.
   PubMed Web of Science ®Google Scholar
• Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–2384.
   PubMed Web of Science ®Google Scholar
• Weerkamp F, Dekking E, Ng YY, et al. Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia. 2009;23:1106–1117.
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Torres F, Ivanova-Dragoeva A, Pereira M, et al. An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation. Leuk Lymphoma. 2007;48:1034–1037.
   PubMed Web of Science ®Google Scholar
• Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia – a possible influence of mdr1 gene expression. Hematol Rep. 2011;3:3.
   Google Scholar
• Hanfstein B, Lauseker M, Hehlmann R, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441–1447.
   PubMed Web of Science ®Google Scholar
• Burmeister T, Schwartz S, Taubald A, et al. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007;92:1699–1702.
   PubMed Web of Science ®Google Scholar
• Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia – retrospective study and review of literature. Leuk Res. 2004;28:579–586.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Castagnetti F, Gugliotta G, et al. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94:S141–S147.
   PubMed Web of Science ®Google Scholar
• Nacheva EP, Grace CD, Brazma D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol. 2013;161:541–550.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.
   PubMed Web of Science ®Google Scholar
• OncLive [Internet]. Leach B: oncology specialty group. Plainsboro (NJ); 2012 [cited 2016 May 31]. Available from: http://www.onclive.com/.
   Google Scholar
• Sweet K, Pinilla-Ibarz J, Zhang L. Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Prefer Adherence. 2014;8:981–986.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Radich JP, Abboud CN, et al. Chronic myelogenous leukemia, version 1.2014. J Natl Compr Canc Netw. 2013;11:1327–1340.
   PubMed Web of Science ®Google Scholar
• Mathisen MS, Kantarjian HM, Cortes J, et al. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014;28:179–187.
   PubMed Web of Science ®Google Scholar
• Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)ALL – role of ponatinib. Biologics. 2014;8:243–254.
   PubMedGoogle Scholar
• Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–1318.
   PubMed Web of Science ®Google Scholar
• Soverini S, Rosti G, Baccarani M, et al. Molecular Monitoring. Curr Hematol Malig Rep. 2014;9:1–8.
   PubMed Web of Science ®Google Scholar
• Press RD, Kamel-Reid S, Ang D. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Mol Diagn. 2013;15:565–576.
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–1215.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–4028.
   PubMed Web of Science ®Google Scholar
• Gréen H, Skoglund K, Rommel F, et al. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol. 2010;66:383–386.
   PubMed Web of Science ®Google Scholar
• Kim YK, Lee SS, Jeong SH, et al. OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib. Chonnam Med J. 2014;50:102–111.
   PubMedGoogle Scholar
• Gromicho M, Dinis J, Magalhães M, et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 2011;52:1980–1990.
   PubMed Web of Science ®Google Scholar
• Gromicho M, Magalhães M, Torres F, et al. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep. 2013;29:741–750.
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010;28:2761–2767.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064–4072.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89:547–556.
   PubMed Web of Science ®Google Scholar
• Deniz T, Osman D, Emel G, Erdal T, Nihal I. Applications of fluorescence in situ hybridization (FISH) for detecting genetic changes in hematological malignancies. J Cancer Ther. 2011;2:5596.
   Google Scholar
• Wolff DJ, Bagg A, Cooley LD, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007;9:134–143.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease – report of the BIOMED-I concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15:556–564.
   PubMed Web of Science ®Google Scholar
• Bolufer P. Standardized quantitative assessment of BCR-ABL1 transcripts on an international scale. Clin Chem. 2013;59:874–875.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2013;20:1–13.
   Web of Science ®Google Scholar
• Cross NCP, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119:1981–1987.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514–2520.
   PubMed Web of Science ®Google Scholar
• Mahon FX. Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012;2012:122–128.
   PubMedGoogle Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Carella AM, Branford S, Deininger M, et al. What challenges remain in chronic myeloid leukemia research? Haematologica. 2013;98:1168–1172.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376:1186–1193.
   PubMed Web of Science ®Google Scholar
• Kanavos P. 2006. The rising burden of cancer in the developing world. Ann Oncol. 2006;17:viii15–viii23.
   PubMed Web of Science ®Google Scholar
• Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53:1593–1600.
   PubMed Web of Science ®Google Scholar
• Cayuela JM, Macintyre E, Darlington M, et al. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica. 2011;96:664–671.
   PubMed Web of Science ®Google Scholar
• Porta G, Pagani IS, Pirrone C. gDNA Q-PCR for clinical monitoring of CML. Cell Cycle. 2015;14:3659.
   PubMed Web of Science ®Google Scholar
• Mattarucchi E, Spinelli O, Rambaldi A, et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol Diagn. 2009;11:482–487.
   PubMed Web of Science ®Google Scholar
• Baer C, Kern W, Koch S, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica. 2016;101:830–838.
   PubMed Web of Science ®Google Scholar
• Polakova KM, Kulvait V, Benesova A, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141:887–899.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Rinke J, Schäfer V, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28:2292–2299.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:1634–1648.
   PubMed Web of Science ®Google Scholar
• Parker WT, Ho M, Scott HS, et al. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012;119:2234–2238.
   PubMed Web of Science ®Google Scholar
• Shibata Y, Malhotra A, Dutta A. Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET. Genome Med. 2010;2:70.
   PubMed Web of Science ®Google Scholar
• Salto-Tellez M, Shelat SG, Benoit B, et al. Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn 2003;5:231–236.
   PubMed Web of Science ®Google Scholar
• Park JS, Yi JW, Jeong SH, et al. Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol. 2008;30:513–518.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Kim HR, Shin MG, et al. Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems. J Korean Med Sci. 2011;26:886–892.
   PubMed Web of Science ®Google Scholar
• Song MJ, Kim HJ, Park CH, et al. Diagnostic utility of a multiplex RT-PCR assay in detecting fusion transcripts from recurrent genetic abnormalities of acute leukemia by WHO 2008 classification. Diagn Mol Pathol. 2012;21:40–44.
   PubMedGoogle Scholar
• Jennings LJ, George D, Czech J, et al. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn. 2014;16:174–179.
   PubMed Web of Science ®Google Scholar
• Brown JT, Laosinchai-Wolf W, Hedges JB, et al. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. Blood Cancer J. 2011;1:e13.
   PubMed Web of Science ®Google Scholar
• Goh HG, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011;52:896–904.
   PubMed Web of Science ®Google Scholar
• Lee AC, Du D, Chen B, et al. Electrochemical detection of leukemia oncogenes using enzyme-loaded carbon nanotube labels. Analyst. 2014;139:4223–4230.
   PubMed Web of Science ®Google Scholar
• Liu A, Sun Z, Wang K, et al. Molecular beacon-based fluorescence biosensor for the detection of gene fragment and PCR amplification products related to chronic myelogenous leukemia. Anal Bioanal Chem. 2012;402:805–812.
   PubMed Web of Science ®Google Scholar
• Cordeiro M, Giestas L, Lima JC, et al. BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia. J Nanobiotechnology. 2016;14:38.
   PubMed Web of Science ®Google Scholar
• Conde J, de la Fuente JM, Baptista PV. RNA quantification using gold nanoprobes – application to cancer diagnostics. J Nanobiotechnology. 2010;8:5.
   PubMedGoogle Scholar
• Conde J, Doria G, de la Fuente JM, et al. RNA quantification using noble metal nanoprobes: simultaneous identification of several different mRNA targets using color multiplexing and application to cancer diagnostics. Methods Mol Biol. 2012;906:71–87.
   PubMedGoogle Scholar
• Baptista PV. RNA quantification with gold nanoprobes for cancer diagnostics. Clin Lab Med. 2012;32:1–13.
   PubMed Web of Science ®Google Scholar
• Vinhas R, Correia C, Ribeiro P, et al. Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes. Anal Bioanal Chem. 2016;408:5277–5284.
   PubMed Web of Science ®Google Scholar
• Rosso V, Bracco E, Pedrola R, et al. Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. Biomark Res. 2015;3:15.
   PubMed Web of Science ®Google Scholar
• Yin P, Choi HM, Calvert CR, et al. Programming biomolecular self-assembly pathways. Nature. 2008;451:318–322.
   PubMed Web of Science ®Google Scholar
• Song C, Xie G, Wang L, et al. DNA-based hybridization chain reaction for an ultrasensitive cancer marker EBNA-1 electrochemical immunosensor. Biosens Bioelectron. 2014;58:68–74.
   PubMed Web of Science ®Google Scholar
• Zhou G, Lin M, Song P, et al. Multivalent capture and detection of cancer cells with DNA nanostructured biosensors and multibranched hybridization chain reaction amplification. Anal Chem. 2014;86:7843–7848.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan Y, Chen W, et al. A simple electrochemical biosensor for highly sensitive and specific detection of microRNA based on mismatched catalytic hairpin assembly. Biosens Bioelectron. 2015;68:343–349.
   PubMed Web of Science ®Google Scholar
• Li J, Lei P, Ding S, et al. An enzyme-free surface plasmon resonance biosensor for real-time detecting microRNA based on allosteric effect of mismatched catalytic hairpin assembly. Biosens Bioelectron. 2016;77:435–441.
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhou W, Li X, et al. Coupling hybridization chain reaction with catalytic hairpin assembly enables non-enzymatic and sensitive fluorescent detection of microRNA cancer biomarkers. Biosens Bioelectron. 2016;77:416–420.
   PubMed Web of Science ®Google Scholar
• Zheng J, Ma D, Shi M, et al. A new enzyme-free quadratic SERS signal amplification approach for circulating microRNA detection in human serum. Chem. Commun. (Camb.). 2015;51:16271–16274.
   PubMed Web of Science ®Google Scholar
• Compton J. Nucleic acid sequence-based amplification. Nature. 1991;350:91–92.
   PubMed Web of Science ®Google Scholar
• Sooknanan R, Malek L, Wang XH, et al. Detection and direct sequence identification of BCR-ABL mRNA in Ph + chronic myeloid leukemia. Exp Hematol. 1993;21:1719–1724.
   PubMed Web of Science ®Google Scholar
• Burchill SA, Perebolte L, Johnston C, et al. Comparison of the RNA-amplification based methods RT-PCR and NASBA for the detection of circulating tumour cells. Br J Cancer. 2002;86:102–109.
   PubMed Web of Science ®Google Scholar
• Langabeer SE, Gale RE, Harvey RC, et al. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia. 2002;16:393–399.
   PubMed Web of Science ®Google Scholar
• Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28:e63.
   PubMed Web of Science ®Google Scholar
• Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes. 2002;16:223–229.
   PubMed Web of Science ®Google Scholar
• Mori Y, Nagamine K, Tomita N, et al. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem Biophys Res Commun. 2001;289:150–154.
   PubMed Web of Science ®Google Scholar
• Tomita N, Mori Y, Kanda H, et al. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. Nat Protoc. 2008;3:877–882.
   PubMed Web of Science ®Google Scholar
• Morishita S, Tani H, Kurata S, et al. Real-time reverse transcription loop-mediated isothermal amplification for rapid and simple quantification of WT1 mRNA. Clin Biochem. 2009;42:515–520.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Rambaldi A, Rigo F, et al. Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology. Oncoscience. 2015;2:50–58.
   PubMedGoogle Scholar
• Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014;32:3077.
   PubMed Web of Science ®Google Scholar
• Hong SH, Kim JI, Kang H, et al. Detection and quantification of the Bcr/Abl chimeric protein on biochips using LDI-TOF MS. Chem. Commun. (Camb.). 2014;50:4831–4834.
   PubMed Web of Science ®Google Scholar
• Yang TY, Eissler CL, Hall MC, et al. A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor. PLoS One. 2013;8:e56627
   PubMed Web of Science ®Google Scholar
• Cabral RM, Baptista PV. Anti-cancer precision theranostics: a focus on multifunctional gold nanoparticles. Expert Rev Mol Diagn. 2014;14:1041–1052.
   PubMed Web of Science ®Google Scholar
• Vinhas R, Cordeiro M, Carlos FF, et al. Gold nanoparticle-based theranostics: disease diagnostics and treatment using a single nanomaterial. Nanobiosens Dis Diagn. 2015;4:11–23.
   Google Scholar
• Pedrosa P, Vinhas R, Fernandes AR, et al. Gold nanotheranostics: proof-of-concept or clinical tool? Nanomaterials. 2015;5:1853–1879.
   Web of Science ®Google Scholar
• Singh A, Dilnawaz F, Sahoo SK. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One. 2011;6:e26803.
   PubMed Web of Science ®Google Scholar